*In a 21-day, Phase II, open-label, multicentre, dose-ranging study evaluating the safety and effect of Revestive in 17 patients with SBS-IF, treatment with Revestive at doses from 0.03 to 0.15 mg/kg/day in single or divided doses. 8 of 10 patients with end jejunostomy were biopsied and found to have increased intestinal villus height and crypt depth, compared with baseline.
** Treatment resulted in enhanced gastrointestinal fluid absorption of approximately 750-1000 mL/day with improvements in the absorption of electrolytes.
GLP-2= glucagon-like peptide-2; SBS-IF= short bowel syndrome – intestinal failure
The information on this website is intended for an international healthcare professional audience outside of the United States, United Kingdom, and Ireland only.